QBX258 treatment increased quality of life and reduced pathologic changes in skin including hyperkeratosis, cytokine production, fibrosis and immune cell recruitment. was to test the efficacy BDNF of QBX258, a monoclonal IL4/IL13 neutralizing antibody, in women with breast cancerCrelated lymphedema (BCRL). We enrolled nine women with unilateral stage I/II BCRL and treated them once monthly […]